



# Profil, Neuss, Germany appoints Professor Hans de Vries as Senior Medical Scientist

NEUSS, GERMANY, November 16, 2017 /EINPresswire.com/ -- Profil, Neuss, Germany, the world's leading full-service contract research organisation for early phase clinical trials in diabetes and obesity, today announced the appointment of Professor Hans de Vries as Senior Medical Scientist. "Dr. de Vries is a world-leading expert in diabetes with a high international reputation for his scientific contributions, in particular in the fields of treatment of type 1 and type 2 diabetes as well as in the development of an artificial pancreas," said Dr. Tim Heise, Lead Scientist and Chairman of the Board of Directors at Profil. "All of us at Profil are very proud that such a renowned scientist joins our team. Dr. de Vries will help us to further expand and improve our scientific activities which set ourselves apart from other contract research organisations."

Dr. de Vries obtained board licenses in Internal Medicine and Endocrinology at the VU University Medical Centre, Amsterdam. He was appointed as professor of Internal Medicine at the University of Amsterdam's Faculty of Medicine in 2016. He will keep this position on a part-time (one day per week) basis. Dr. de Vries has been Principal Investigator in numerous clinical trials and has published more than 200 peer-reviewed scientific publications. He is a frequently invited speaker at international diabetes meetings, an editorial board member of *Diabetes Care*, the *Journal of Diabetes Science and Technology*, and International Associate Editor of *Diabetes Technology & Therapeutics*. Dr. de Vries has been scientific coordinator of AP@home and PCDIAB, EU-funded consortia focused on closed loop system, in which also Profil was involved.

The expansion of resources with such a renowned expert allows Profil to further improve its offerings in project design and consulting services, upstream of the trial conduct phase. This area has been a particular strength of Profil from the beginning and has allowed the company to set itself apart from competition. As a boutique CRO, unlike most, Profil has continued to focus on diabetes, obesity and related disorders. This has allowed the company to retain and build world-leading scientific expertise and reputation in this area, nothing short of a leading academic centre. However, in the setting of a private CRO, Profil has been able to combine this scientific acumen with regulatory affairs and quality control processes that are hard to provide in a university setting, making Profil unique in its offering.

As Profil continues to grow, the company is adding not only scientific resources, but has also expanded office and clinic space at both sites in Neuss and Mainz. Further, Profil is adding another 6 ClampArt® devices, recruiting further staff in- and outside the clinics and investing heavily in the expansion of the subject database of volunteers with and without diabetes. These investments along the whole workflow ensure availability of world-class resources for existing and future clients and allow Profil to accelerate the search for answers for diabetes.

## About Profil

Profil, founded in 1999 as a spin-off of an academic study group at the University of Düsseldorf, quickly developed to the world's leading full-service CRO for early phase clinical trials in diabetes and obesity. With its unique combination of regulatory and scientific expertise one of Profil's strengths is the pharmacodynamic characterisation of the metabolic effects of anti-diabetic compounds using sophisticated experimental methods, in particular the glucose clamp technique, often combined with

isotope dilution techniques and muscle or fat biopsies. Profil have recently enlarged their clamp capacity in their two sites in Neuss and Mainz with additional ClampArt® devices, Profil's proprietary automated glucose clamp device. With 28 clamp beds and 80 clinical beds in total, Profil is the largest glucose clamp center worldwide.

Profil's renowned scientists have largely contributed to the development of nearly all the currently available major anti-diabetic compounds. In 2017, Profil's scientists have co-authored around 40 scientific publications in peer-reviewed journals. In addition, Profil have been recruited additional staff in- and outside the clinics and have heavily invested in the expansion of their patient database. These investments will ensure the availability of world-class resources to Profil's clients and will allow Profil to accelerate the search for answers for diabetes.

[www.profil.com](http://www.profil.com)

Dr. Lars Bochmann  
Profil Institut für Stoffwechselforschung GmbH  
+49 (0) 2131 4018 0  
email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.